top of page
Image by Testalize.me

Dunweimei Group
A leader in medical aesthetic microspheres and needle-free injection solutions.

Redefining the injection experience with cutting-edge technology.

Halal and ESG certified

Screenshot from 1:21 PM on September 20, 2025 (edited).png
Screenshot taken on September 18, 2025 at 11:34:44 AM.png
Screenshot from 2025-09-20 at 1:21:28 PM.png

Our mission

Focusing on the development of medical aesthetics technology and needle-free injection devices, we possess comprehensive integrated capabilities from microsphere material design, equipment engineering, formulation to end product development.

Research and Technology

It possesses comprehensive integrated capabilities encompassing microsphere material design, equipment engineering, formulation, and end-product manufacturing.

Our mission

"Making every injection safer and better," through independent research and development, scientific design, and industry integration, we provide global users with safe, efficient, and affordable innovative injection solutions.

1

Liraglutide | GLP-1
Speedy Fiber™

2

Deoxycholic acid
Liposuction Needle™

3

Nalbuphine
Non-capsulated analgesics

4

Epinephrine emergency injection
Anminhu™

Dunweimei Group

We offer integrated professional services spanning medical aesthetic products, pharmaceutical development, and drug delivery equipment. We are committed to becoming Taiwan's first dual-platform service provider centered on "microsphere technology" and "needle-free injection platform."

我們注重

Innovation, safety, and human-centered design

Our mission is to "make every injection safer and better," providing safe, efficient, and affordable innovative injection solutions to users worldwide through independent research and development, scientific design, and industry integration. Safer facial implants significantly reduce the risk of nodules and emboli.

Zhang Zhenzhong

Chairman and Founder

Gemini_Generated_Image_zbiuf9zbiuf9zbiu_edited.jpg

milestone

4 items

New patent

3 items

Invention Patent

Product Certification

Professional

Services

We are committed to becoming Taiwan's first dual-platform service provider with "microsphere technology" and "needle-free injection platform" as our core technologies.

We offer proprietary patented "eggshell-shaped microsphere" technology platform (PLLA / PDLLA / PCL) for the development and customized production of fillers, lifting agents, and other products.

Development and contract manufacturing of microsphere collagen stimulants

Patented high-pressure driven air needle device, suitable for injecting aqueous microparticles and emergency injections. OEM/ODM services available: device housing design, air pressure calibration, and user operation simulation testing.

Needle-free injection device design and integration

Assist clinics/distributors in building their brands (filler + equipment integration package) in conjunction with MIZE injections, PIVIS microspheres, or custom-developed new formulas.

Customized brand and white-label medical aesthetic products services

Includes: PLGA/PLA depot, cryo-injectables, liposomes, and a complete development process for nanoparticles: Pre-formulation → Scale-up → Registration

Advanced Injectable Drug Development Services

Develop dosage forms of GLP-1, analgesics, adrenaline, etc., to be used with needle-free injection devices, and support Human Factor Study and QMS document and regulatory certification preparation.

Integrated development of drug combination devices

When used in conjunction with GMP-compliant plants (filling/crystallization/packaging), it supports TFDA, US FDA, and EU CTD declaration formats.

Integrated services for contract manufacturing and outsourced development

We support patent applications in Taiwan, China, the United States, and the European Union, providing FTO (Freedom to Operate) analysis and patent drafting services.

Product patent and regional application layout

Support the establishment of TFDA / CE / ISO 13485 medical device related documents and audit systems, and assist startups in implementing QMS, design verification, and risk assessment processes.

Medical Device Registration and Quality System Establishment

blogger

No posts published in this language yet
Once posts are published, you’ll see them here.

Press

BGS appoints Andrew Kim as Board Director

AGIAI Science Journal
November 2035

Therapeutics Giant Announces Collaboration With San Francisco's BGS

Biotech Frontier Review
May 2035

There's a New Kid in Town, Changing the Face of Genetic Engineering.

IBRM Magazine
March 2035

Learn more and subscribe to our newsletter!

To make every injection safer and better.

bottom of page